V8 Peptides — Engineered Performance
Research Library
KLOW Stack Gut and Immune Models: KPV and BPC-157
KLOW StackStacks

KLOW Stack Gut and Immune Models: KPV and BPC-157

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What do intestinal models report for KPV and BPC-157? KPV, the C-terminal tripeptide of α-MSH, inhibited NF-κB and MAP kinase signaling at nanomolar concentrations in intestinal epithelial and T-cell lines, acting through the PepT1 di/tripeptide transporter, and reduced inflammation readouts in DSS and TNBS colitis in mice. BPC-157 is described in reviews as a stable gastric pentadecapeptide with effects reported in GI models, with Egr-1, NAB2, FAK-paxillin and JAK-2 pathways implicated. The two peptides act through different proposed routes, and no study cited here tests them together. The KLOW Stack supplies both, plus GHK-Cu and TB-500, in one 80 mg vial. This article reads the gut-model literature and sets out a controlled design. Laboratory research use only.

The KLOW Stack combines four peptides, and two of them, KPV and BPC-157, have their strongest literature in intestinal and immune models. That makes a gut-and-immune angle a natural one to examine, as long as it stays at the level of cell and animal findings. Here the aim is to explain how KPV gets into cells, what its models measured, how BPC-157 is described in the GI literature, and how to design an experiment in which the two can be separated. For the skin-and-matrix side of the blend see the KLOW skin and tissue models article. Product facts are on the KLOW Stack product page; the compound summaries are in the KLOW Stack research overview, KPV research overview and BPC-157 research overview.

KPV: a transporter-dependent tripeptide

KPV is the three-residue C-terminal fragment of α-MSH, Lys-Pro-Val. A review of α-MSH and related tripeptides describes the parent hormone as having protective and anti-inflammatory effects in many models and presents KPV as an alternative that retains the anti-inflammatory activity without the pigmentary action of the full hormone (Brzoska 2008). The mechanistic question for KPV is how a charged tripeptide enters a cell. Dalmasso and colleagues addressed it directly: using Caco2-BBE and HT29-Cl.19A intestinal epithelial cells and Jurkat T cells stimulated with pro-inflammatory cytokines, they found that nanomolar concentrations of KPV inhibited activation of NF-κB and MAP kinase signaling and reduced pro-inflammatory cytokine secretion, and that KPV acts via PepT1, a di/tripeptide transporter expressed in immune and intestinal epithelial cells (Dalmasso 2008). The same paper reported that KPV given in drinking water reduced inflammation in DSS- and TNBS-induced colitis in mice. A companion piece is KPV and PepT1 uptake.

StudySystemWhat was measured
Dalmasso 2008Caco2-BBE, HT29-Cl.19A, Jurkat cells; DSS and TNBS colitis in miceNF-κB luciferase reporter, MAP kinase, cytokines, PepT1 uptake kinetics, histology and cytokine mRNA
Kannengiesser 2008DSS colitis and CD45RBhi transfer colitis in mice; melanocortin-1 receptor-nonfunctional miceWeight, histology and myeloperoxidase activity
Xiao 2017Hyaluronic acid-functionalized nanoparticles loaded with KPV; mouse colitis modelParticle size of about 272 nm, delivery to colonic epithelial cells and macrophages, TNF-α and mucosal damage
Brzoska 2008Reviewα-MSH and KPV effects on NF-κB, cytokines and immune cells

The Kannengiesser paper adds a detail worth noting: it used mice with a nonfunctional melanocortin-1 receptor, an arm designed to ask whether the receptor was needed for KPV activity (Kannengiesser 2008). The PepT1 result in the Dalmasso paper and the receptor question in this one are two different mechanistic framings of the same peptide, and a design that reports one should say that the other was not tested.

BPC-157 in the GI literature

BPC-157 is a 15-residue peptide, sequence GEPPPGKPADDAGLV with a molecular weight of about 1419 according to one review, described as stable in human gastric juice (Sikiric 2012). The brain–gut axis review summarizes work in which BPC-157 is positioned as a mediator of cytoprotection involved in maintaining GI mucosal integrity, and lists Egr-1, NAB2, FAK-paxillin and JAK-2 pathways as implicated so far (Sikiric 2016). The ulcerative-colitis-focused review gathers animal findings on anastomosis, fistula and mucosal models and notes interaction with the nitric oxide system (Sikiric 2012). Both BPC-157 reviews cited here are authored by the same group, a point worth stating in any methods section that relies on them. See also BPC-157 research overview and BPC-157 vs TB-500.

The mechanistic ideas are different from KPV’s. KPV is described through transporter-dependent uptake and inhibition of inflammatory signaling in epithelial and immune cells; BPC-157 is described through growth-factor and signaling-pathway involvement and through effects on the endothelium. Because the proposed routes differ, a blend of the two could in principle show additive effects, overlapping effects on the same endpoint, or none, and the literature cited here cannot say which.

Designing a gut-model experiment that can separate the components

ArmPurpose
VehicleBaseline cytokine, NF-κB and barrier readouts
Stimulus alone (e.g. cytokine cocktail)Defines the inflammatory window
KPV alone, range of molar concentrationsSingle-component response
BPC-157 alone, range of molar concentrationsSingle-component response
KPV + BPC-157 at matched molar concentrationsTests additive versus interacting behavior
Blend with GHK-Cu and TB-500 presentTests whether added components alter the response
Competing PepT1 substrate (e.g. another di/tripeptide)Tests whether KPV uptake is transporter-dependent in the chosen cells
Copper-matched controlAccounts for the copper carried by GHK-Cu

Cell choice follows the question. Caco-2-type monolayers are standard for barrier and uptake experiments and express PepT1 under some conditions; HT29 lines serve for signaling; macrophage and T-cell lines serve for cytokine read-outs. Co-culture or transwell systems combine the epithelium and immune cells and are closer to the tissue. Whichever is used, verify PepT1 expression, because the transporter’s level changes with differentiation and with inflammation, a point stated in the cited abstract for the colon (Dalmasso 2008).

Read-outs and what each can establish

Signaling read-outs, such as an NF-κB luciferase reporter and MAP kinase phosphorylation, are fast and quantitative but show pathway activity, not tissue outcome. Cytokine secretion by ELISA or multiplex assay measures the output of those pathways. Barrier function, measured by transepithelial electrical resistance and a paracellular tracer, tests a different property. Histology and myeloperoxidase activity appear in the animal colitis studies and cannot be measured in a simple cell culture. A study that claims a gut effect should specify which of those levels was measured, because a change in a reporter is not a change in barrier function, and neither is a histology score.

Concentration planning uses C = m / (MW × V) for each peptide with its own molecular weight and C1V1 = C2V2 for dilutions. Because the vial is a blend and the product page does not state the per-component mass split, take the composition from the certificate, where published, in the COA library. The reconstitution calculator covers vial arithmetic and KLOW Stack reconstitution and storage covers handling of the four-peptide vial.

Interpreting a combined result

Suppose a design like the one above shows a larger reduction in a cytokine read-out with the KPV-plus-BPC-157 arm than with either alone. Three explanations compete. The effects could be additive, each acting through its own route on a shared endpoint. They could be interacting, for instance if one peptide changes the uptake or stability of the other. Or the difference could be an artifact, such as a change in the amount of free peptide because the two adsorb to plastic differently in a mixture. The arms listed in the table are meant to separate these: the competing-substrate arm tests the uptake route, the matched-molar single arms define the additive expectation, and a recovery measurement on the mixture, by HPLC of the medium at the start and end of the incubation, tests the artifact explanation.

If the combined response is indistinguishable from the stronger single component, that is a clear result too: it indicates that the second peptide adds nothing detectable in that assay, which is useful information for anyone deciding whether a blend is necessary for a given question. Reporting such null combinations is as valuable as reporting synergy, and it helps correct the impression, common in catalog language, that more components must mean more activity.

Limits of the gut literature

Three limits should travel with any summary. First, mouse colitis models differ from each other in cause and course, so a finding in a DSS model does not automatically hold in a transfer model. Second, oral delivery of a peptide to the colon is an obstacle, which is why a delivery study such as the hyaluronic acid nanoparticle work exists at all (Xiao 2017); results from a delivery vehicle are not results for the free peptide. Third, most findings come from single reports without independent replication in the abstracts used here. None of this lowers the value of the studies as sources of hypotheses; it only calibrates how they should be cited.

The catalog is on the shop page. All material is for laboratory research use only; not for human or animal consumption.

Frequently asked questions

How does KPV enter cells?

In the cited study it acted via PepT1, a di/tripeptide transporter expressed in intestinal epithelial and immune cells, and uptake was characterized with a competing substrate and with radiolabeled KPV.

What concentrations of KPV were active in vitro?

Nanomolar concentrations inhibited NF-kB and MAP kinase signaling and reduced cytokine secretion in the cited cell models.

Which colitis models used KPV?

DSS and TNBS colitis in the PepT1 paper, and DSS colitis and CD45RB-high transfer colitis in the melanocortin paper.

Why was a melanocortin-1 receptor-nonfunctional mouse used?

To ask whether KPV activity required that receptor; the abstract describes the exposure of these animals in the DSS model.

What is BPC-157 described as in the GI literature?

A stable gastric pentadecapeptide described as stable in human gastric juice, with Egr-1, NAB2, FAK-paxillin and JAK-2 pathways implicated.

Do KPV and BPC-157 share a mechanism?

They are described through different proposed routes: transporter-dependent uptake and NF-kB inhibition for KPV, growth-factor and signaling pathways for BPC-157.

Has the KLOW Stack been tested in gut models?

Not in the sources cited here. The evidence is component-level.

What controls separate the components?

Single-component arms at matched molar concentrations, a pairwise arm, the full blend, a competing PepT1 substrate and a copper-matched control.

Why does the nanoparticle study matter for interpretation?

It tests a delivery vehicle for KPV, so its results describe the vehicle-peptide combination and not the free peptide.

Where is the per-component composition stated?

The product page lists 80 mg total; component identity is reported on the batch certificate where published.

Related reading: KLOW Stack Storage: Temperature, Light and Shelf Life, KLOW vs GLOW Stack: What KPV Adds to the Blend, KPV in the KLOW Stack: Gut and Inflammation Research.

References

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026
  2. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. doi:10.1002/ibd.20334
  3. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. doi:10.1210/er.2007-0027
  4. Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640. doi:10.1016/j.ymthe.2016.11.020
  5. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153022
  6. Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012;19(1):126-132. doi:10.2174/092986712803414015

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.